| Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer | TA1017 | | |
| Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis | TA1018 | | |
| Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over | TA1019 | | |
| Elafibranor for previously treated primary biliary cholangitis | TA1016 | | |
| Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer | TA1014 | | |
| Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments | TA1015 | | |
| Avapritinib for treating advanced systemic mastocytosis | TA1012 | | |
| Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria | TA1010 | | |
| Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia | TA1013 | | |
| Belzutifan for treating tumours associated with von Hippel-Lindau disease | TA1011 | | |
| Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension | TA1009 | | |
| Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments | TA1008 | | |
| Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer | TA1007 | | |
| Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal) | TA1006 | | |
| Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over | TA1002 | | |
| Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over | TA1003 | | |
| Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion | TA1004 | | |
| Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement | TA1005 | | |
| Iptacopan for treating paroxysmal nocturnal haemoglobinuria | TA1000 | | |
| Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment | TA1001 | | |
| Vibegron for treating symptoms of overactive bladder syndrome | TA999 | | |
| Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma | TA997 | | |
| Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer | TA737 | | |
| Risankizumab for treating moderately to severely active ulcerative colitis | TA998 | | |
| Relugolix for treating hormone-sensitive prostate cancer | TA995 | | |
| Linzagolix for treating moderate to severe symptoms of uterine fibroids | TA996 | | |
| Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy (terminated appraisal) | TA994 | | |
| Abaloparatide for treating osteoporosis after menopause | TA991 | | |
| Burosumab for treating X-linked hypophosphataemia in adults | TA993 | | |
| Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy | TA992 | | |
| Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis | TA988 | | |
| Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B | TA989 | | |
| Tenecteplase for treating acute ischaemic stroke | TA990 | | |
| Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over | TA986 | | |
| Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal) | TA987 | | |
| Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma | TA985 | | |
| Selective internal radiation therapies for treating hepatocellular carcinoma | TA688 | | |
| Tafamidis for treating transthyretin amyloidosis with cardiomyopathy | TA984 | | |
| Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal) | TA982 | | |
| Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma | TA983 | | |
| Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation | TA979 | | |
| Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal) | TA980 | | |
| Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) | TA976 | | |
| Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over | TA977 | | |
| Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal) | TA978 | | |
| Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal) | TA972 | | |
| Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis | TA127 | | |
| Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis | TA312 | | |
| Cladribine for treating relapsing–remitting multiple sclerosis | TA616 | | |
| Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion | TA283 | | |
| Ranibizumab and pegaptanib for the treatment of age-related macular degeneration | TA155 | | |
| Ranibizumab for treating choroidal neovascularisation associated with pathological myopia | TA298 | | |
| Atogepant for preventing migraine | TA973 | | |
| Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma | TA974 | | |
| Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under | TA975 | | |
| Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments | TA970 | | |
| Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 | TA971 | | |
| Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over | TA967 | | |
| Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma | TA540 | | |
| Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal) | TA969 | | |
| Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA968 | | |
| Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal) | TA966 | | |
| Cabozantinib with nivolumab for untreated advanced renal cell carcinoma | TA964 | | |
| Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency | TA963 | | |
| Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal) | TA961 | | |
| Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy | TA962 | | |
| Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal) | TA965 | | |
| Ritlecitinib for treating severe alopecia areata in people 12 years and over | TA958 | | |
| Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis | TA959 | | |
| Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal) | TA960 | | |
| Momelotinib for treating myelofibrosis-related splenomegaly or symptoms | TA957 | | |
| Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 | TA878 | | |
| Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema | TA953 | | |
| Dupilumab for treating moderate to severe prurigo nodularis | TA955 | | |
| Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over | TA956 | | |
| Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments | TA954 | | |
| Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations | TA952 | | |
| Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over | TA949 | | |
| Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over | TA950 | | |
| Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer | TA951 | | |
| Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments | TA947 | | |
| Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments | TA948 | | |
| Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal) | TA945 | | |
| Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer | TA946 | | |
| Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer | TA944 | | |
| Targeted-release budesonide for treating primary IgA nephropathy | TA937 | | |
| Ravulizumab for treating generalised myasthenia gravis (terminated appraisal) | TA940 | | |
| Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal) | TA941 | | |
| Empagliflozin for treating chronic kidney disease | TA942 | | |
| Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes | TA943 | | |
| Risdiplam for treating spinal muscular atrophy | TA755 | | |
| Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer | TA939 | | |
| Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal) | TA938 | | |
| Secukinumab for treating moderate to severe hidradenitis suppurativa | TA935 | | |
| Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal) | TA936 | | |
| Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal) | TA933 | | |
| Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms | TA934 | | |
| Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal) | TA932 | | |
| Zanubrutinib for treating chronic lymphocytic leukaemia | TA931 | | |
| Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments | TA930 | | |
| Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction | TA929 | | |
| Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine | TA928 | | |
| Ranibizumab for treating diabetic macular oedema | TA274 | | |
| Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable | TA917 | | |
| Tirzepatide for treating type 2 diabetes | TA924 | | |
| Mirikizumab for treating moderately to severely active ulcerative colitis | TA925 | | |
| Baricitinib for treating severe alopecia areata | TA926 | | |
| Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal) | TA923 | | |
| Rimegepant for treating migraine | TA919 | | |
| Tofacitinib for treating active ankylosing spondylitis | TA920 | | |
| Ruxolitinib for treating polycythaemia vera | TA921 | | |
| Daridorexant for treating long-term insomnia | TA922 | | |
| Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments | TA927 | | |
| Bimekizumab for treating axial spondyloarthritis | TA918 | | |
| Pegunigalsidase alfa for treating Fabry disease | TA915 | | |
| Bimekizumab for treating active psoriatic arthritis | TA916 | | |
| Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency | TA914 | | |
| Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy | TA913 | | |
| Semaglutide for managing overweight and obesity | TA875 | | |
| Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease | TA912 | | |
| Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer | TA911 | | |
| Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal) | TA910 | | |
| Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer | TA909 | | |
| Rimegepant for preventing migraine | TA906 | | |
| Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy | TA908 | | |
| Deucravacitinib for treating moderate to severe plaque psoriasis | TA907 | | |
| Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction | TA902 | | |
| Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer | TA903 | | |
| Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer | TA904 | | |
| Upadacitinib for previously treated moderately to severely active Crohn's disease | TA905 | | |
| Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal) | TA901 | | |
| Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer | TA898 | | |
| Tixagevimab plus cilgavimab for preventing COVID-19 | TA900 | | |
| Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma | TA894 | | |
| Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy | TA895 | | |
| Bulevirtide for treating chronic hepatitis D | TA896 | | |
| Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over | TA893 | | |
| Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma | TA897 | | |
| Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal) | TA899 | | |
| Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia | TA891 | | |
| Mosunetuzumab for treating relapsed or refractory follicular lymphoma | TA892 | | |
| Risankizumab for previously treated moderately to severely active Crohn's disease | TA888 | | |
| Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA889 | | |
| Difelikefalin for treating pruritus in people having haemodialysis | TA890 | | |
| Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy | TA886 | | |
| Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer | TA887 | | |
| Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments | TA881 | | |
| Voclosporin with mycophenolate mofetil for treating lupus nephritis | TA882 | | |
| Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma | TA883 | | |
| Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal) | TA884 | | |
| Tezepelumab for treating severe asthma | TA880 | | |
| Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal) | TA879 | | |
| Finerenone for treating chronic kidney disease in type 2 diabetes | TA877 | | |
| Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer | TA876 | | |
| Eptinezumab for preventing migraine | TA871 | | |
| Cannabidiol for treating seizures caused by tuberous sclerosis complex | TA873 | | |
| Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma | TA874 | | |
| Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies | TA872 | | |
| Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma | TA870 | | |
| Mitapivat for treating pyruvate kinase deficiency (terminated appraisal) | TA867 | | |
| Vutrisiran for treating hereditary transthyretin-related amyloidosis | TA868 | | |
| Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma | TA865 | | |
| Regorafenib for previously treated metastatic colorectal cancer | TA866 | | |
| Upadacitinib for treating active non-radiographic axial spondyloarthritis | TA861 | | |
| Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments | TA862 | | |
| Somatrogon for treating growth disturbance in children and young people aged 3 years and over | TA863 | | |
| Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted | TA864 | | |
| Maribavir for treating refractory cytomegalovirus infection after transplant | TA860 | | |
| Angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock (terminated appraisal) | TA859 | | |
| Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma | TA857 | | |
| Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma | TA858 | | |
| Upadacitinib for treating moderately to severely active ulcerative colitis | TA856 | | |
| Avatrombopag for treating primary chronic immune thrombocytopenia | TA853 | | |
| Cabozantinib for previously treated advanced hepatocellular carcinoma | TA849 | | |
| Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy | TA850 | | |
| Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer | TA851 | | |
| Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments | TA852 | | |
| Esketamine nasal spray for treatment-resistant depression | TA854 | | |
| Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal) | TA848 | | |
| Mepolizumab for treating eosinophilic granulomatosis with polyangiitis (terminated appraisal) | TA845 | | |
| Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal) | TA846 | | |
| Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal) | TA847 | | |
| Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal) | TA844 | | |
| Luspatercept for treating anaemia caused by beta-thalassaemia (terminated appraisal) | TA843 | | |
| Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA841 | | |
| Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies (terminated appraisal) | TA842 | | |
| Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids (terminated appraisal) | TA839 | | |
| Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids
(terminated appraisal) | TA840 | | |
| Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis (terminated appraisal) | TA838 | | |
| Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma | TA837 | | |
| Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA836 | | |
| Pembrolizumab for adjuvant treatment of renal cell carcinoma | TA830 | | |
| Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids | TA832 | | |
| Zanubrutinib for treating Waldenstrom's macroglobulinaemia | TA833 | | |
| Fostamatinib for treating refractory chronic immune thrombocytopenia | TA835 | | |
| SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (terminated appraisal) | TA834 | | |
| Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy | TA827 | | |
| Ozanimod for treating moderately to severely active ulcerative colitis | TA828 | | |
| Upadacitinib for treating active ankylosing spondylitis | TA829 | | |
| Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer | TA823 | | |
| Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis | TA825 | | |
| Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal) | TA826 | | |
| Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal) | TA822 | | |
| Dexamethasone intravitreal implant for treating diabetic macular oedema | TA824 | | |
| Brolucizumab for treating diabetic macular oedema | TA820 | | |
| Avalglucosidase alfa for treating Pompe disease | TA821 | | |
| Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies | TA819 | | |
| Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma | TA818 | | |
| Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA815 | | |
| Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer | TA816 | | |
| Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence | TA817 | | |
| Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer | TA812 | | |
| Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors | TA813 | | |
| Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis | TA814 | | |
| Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal) | TA811 | | |
| Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease | TA809 | | |
| Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence | TA810 | | |
| Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA803 | | |
| Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides | TA805 | | |
| Belimumab for treating lupus nephritis (terminated appraisal) | TA806 | | |
| Roxadustat for treating symptomatic anaemia in chronic kidney disease | TA807 | | |
| Fenfluramine for treating seizures associated with Dravet syndrome | TA808 | | |
| Teduglutide for treating short bowel syndrome | TA804 | | |
| Faricimab for treating diabetic macular oedema | TA799 | | |
| Faricimab for treating wet age-related macular degeneration | TA800 | | |
| Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer | TA801 | | |
| Cemiplimab for treating advanced cutaneous squamous cell carcinoma | TA802 | | |
| Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation | TA798 | | |
| Venetoclax for treating chronic lymphocytic leukaemia | TA796 | | |
| Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal) | TA797 | | |
| Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal) | TA793 | | |
| Diroximel fumarate for treating relapsing–remitting multiple sclerosis | TA794 | | |
| Ibrutinib for treating Waldenstrom's macroglobulinaemia | TA795 | | |
| Filgotinib for treating moderately to severely active ulcerative colitis | TA792 | | |
| TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices (terminated appraisal) | TA790 | | |
| Romosozumab for treating severe osteoporosis | TA791 | | |
| Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations | TA789 | | |
| Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy | TA788 | | |
| Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies | TA786 | | |
| Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable | TA787 | | |
| Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer | TA784 | | |
| Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal) | TA785 | | |
| Daratumumab monotherapy for treating relapsed and refractory multiple myeloma | TA783 | | |
| Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer | TA781 | | |
| Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal) | TA782 | | |
| Nivolumab with ipilimumab for untreated advanced renal cell carcinoma | TA780 | | |
| Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency | TA779 | | |
| Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal) | TA774 | | |
| Empagliflozin for treating chronic heart failure with reduced ejection fraction | TA773 | | |
| Dapagliflozin for treating chronic kidney disease | TA775 | | |
| Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea | TA776 | | |
| Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea | TA777 | | |
| Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria | TA778 | | |
| Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies | TA772 | | |
| Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer | TA770 | | |
| Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal) | TA771 | | |
| Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (terminated appraisal) | TA762 | | |
| Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable | TA763 | | |
| Fremanezumab for preventing migraine | TA764 | | |
| Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable | TA765 | | |
| Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma | TA766 | | |
| Ponesimod for treating relapsing–remitting multiple sclerosis | TA767 | | |
| Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs | TA768 | | |
| Palforzia for treating peanut allergy in children and young people | TA769 | | |
| Sodium zirconium cyclosilicate for treating hyperkalaemia | TA599 | | |
| Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection | TA761 | | |
| Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer | TA760 | | |
| Cabotegravir with rilpivirine for treating HIV-1 | TA757 | | |
| Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy | TA758 | | |
| Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis | TA756 | | |
| Belimumab for treating active autoantibody-positive systemic lupus erythematosus | TA752 | | |
| Cenobamate for treating focal onset seizures in epilepsy | TA753 | | |
| Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome | TA754 | | |
| Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal) | TA750 | | |
| Dupilumab for treating severe asthma with type 2 inflammation | TA751 | | |
| Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders | TA748 | | |
| Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal) | TA749 | | |
| Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer | TA746 | | |
| Nintedanib for treating progressive fibrosing interstitial lung diseases | TA747 | | |
| Upadacitinib for treating moderate rheumatoid arthritis | TA744 | | |
| NBTXR-3 for treating advanced soft tissue sarcoma (terminated appraisal) | TA745 | | |
| Selpercatinib for treating advanced thyroid cancer with RET alterations | TA742 | | |
| Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer | TA740 | | |
| Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer | TA741 | | |
| Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable | TA739 | | |
| Tofacitinib for treating juvenile idiopathic arthritis | TA735 | | |
| Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy | TA736 | | |
| Berotralstat for preventing recurrent attacks of hereditary angioedema | TA738 | | |
| Secukinumab for treating moderate to severe plaque psoriasis in children and young people | TA734 | | |
| Baloxavir marboxil for treating acute uncomplicated influenza (terminated appraisal) | TA732 | | |
| Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia | TA733 | | |
| Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal) | TA730 | | |
| Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal) | TA731 | | |
| Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA726 | | |
| Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA727 | | |
| Midostaurin for treating advanced systemic mastocytosis | TA728 | | |
| Sapropterin for treating hyperphenylalaninaemia in phenylketonuria | TA729 | | |
| Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA725 | | |
| Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer | TA724 | | |
| Bimekizumab for treating moderate to severe plaque psoriasis | TA723 | | |
| Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement | TA722 | | |
| Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndrome | TA139 | | |
| Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma | TA720 | | |
| Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer | TA721 | | |
| Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency | TA716 | | |
| Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies (terminated appraisal) | TA717 | | |
| Ixekizumab for treating axial spondyloarthritis | TA718 | | |
| Secukinumab for treating non-radiographic axial spondyloarthritis | TA719 | | |
| Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) | TA714 | | |
| Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | | |
| Enzalutamide for treating hormone-sensitive metastatic prostate cancer | TA712 | | |
| Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy | TA713 | | |
| Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation | TA249 | | |
| Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation | TA256 | | |
| Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation | TA355 | | |
| Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation | TA275 | | |
| Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis | TA708 | | |
| Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency | TA709 | | |
| Ravulizumab for treating atypical haemolytic uraemic syndrome | TA710 | | |
| Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer | TA707 | | |
| Ozanimod for treating relapsing–remitting multiple sclerosis | TA706 | | |
| Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer | TA705 | | |
| Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal) | TA702 | | |
| Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal) | TA703 | | |
| Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies | TA704 | | |
| Ravulizumab for treating paroxysmal nocturnal haemoglobinuria | TA698 | | |
| Ofatumumab for treating relapsing multiple sclerosis | TA699 | | |
| Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal) | TA701 | | |
| Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban | TA697 | | |
| Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy | TA692 | | |
| Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia | TA694 | | |
| Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma | TA695 | | |
| Avelumab for treating metastatic Merkel cell carcinoma | TA517 | | |
| Acalabrutinib for treating chronic lymphocytic leukaemia | TA689 | | |
| Avelumab for untreated metastatic Merkel cell carcinoma | TA691 | | |
| Anakinra for treating Still's disease | TA685 | | |
| Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) | TA686 | | |
| Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA687 | | |
| Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease | TA684 | | |
| Erenumab for preventing migraine | TA682 | | |
| Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer | TA683 | | |
| Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma | TA680 | | |
| Baricitinib for treating moderate to severe atopic dermatitis | TA681 | | |
| Filgotinib for treating moderate to severe rheumatoid arthritis | TA676 | | |
| Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma | TA677 | | |
| Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) | TA678 | | |
| Dapagliflozin for treating chronic heart failure with reduced ejection fraction | TA679 | | |
| Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy | TA673 | | |
| Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal) | TA674 | | |
| Vernakalant for the rapid conversion of recent onset atrial fibrillation to sinus rhythm (terminated appraisal) | TA675 | | |
| Trabectedin for the treatment of advanced soft tissue sarcoma | TA185 | | |
| Mepolizumab for treating severe eosinophilic asthma | TA671 | | |
| Brolucizumab for treating wet age-related macular degeneration | TA672 | | |
| Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor | TA670 | | |
| Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer | TA668 | | |
| Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma | TA666 | | |
| Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura | TA667 | | |
| Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia | TA663 | | |
| Liraglutide for managing overweight and obesity | TA664 | | |
| Upadacitinib for treating severe rheumatoid arthritis | TA665 | | |
| Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer | TA660 | | |
| Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma | TA661 | | |
| Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal) | TA662 | | |
| Drug-eluting stents for the treatment of coronary artery disease | TA152 | | |
| Guidance on the use of coronary artery stents | TA71 | | |
| Siponimod for treating secondary progressive multiple sclerosis | TA656 | | |
| Carfilzomib for previously treated multiple myeloma | TA657 | | |
| Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma | TA658 | | |
| Galcanezumab for preventing migraine | TA659 | | |
| Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy | TA655 | | |
| Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer | TA653 | | |
| Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer | TA654 | | |
| Pembrolizumab with axitinib for untreated advanced renal cell carcinoma | TA650 | | |
| Naldemedine for treating opioid-induced constipation | TA651 | | |
| Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma | TA649 | | |
| Dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) | TA648 | | |
| Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal) | TA646 | | |
| Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal) | TA647 | | |
| Avelumab with axitinib for untreated advanced renal cell carcinoma | TA645 | | |
| Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma | TA641 | | |
| Gilteritinib for treating relapsed or refractory acute myeloid leukaemia | TA642 | | |
| Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer | TA643 | | |
| Entrectinib for treating NTRK fusion-positive solid tumours | TA644 | | |
| Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant | TA640 | | |
| Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer | TA638 | | |
| Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer | TA639 | | |
| Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal) | TA634 | | |
| Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal) | TA635 | | |
| Eculizumab for treating refractory myasthenia gravis (terminated appraisal) | TA636 | | |
| Ranibizumab for treating diabetic retinopathy (terminated appraisal) | TA637 | | |
| Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure | TA626 | | |
| Ustekinumab for treating moderately to severely active ulcerative colitis | TA633 | | |
| Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer | TA632 | | |
| Larotrectinib for treating NTRK fusion-positive solid tumours | TA630 | | |
| Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer | TA628 | | |
| Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab | TA629 | | |
| Lenalidomide with rituximab for previously treated follicular lymphoma | TA627 | | |
| Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated appraisal) | TA625 | | |
| Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis | TA624 | | |
| Patiromer for treating hyperkalaemia | TA623 | | |
| Sotagliflozin with insulin for treating type 1 diabetes | TA622 | | |
| Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal) | TA618 | | |
| Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure | TA617 | | |
| Cannabidiol with clobazam for treating seizures associated with Dravet syndrome | TA614 | | |
| Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome | TA615 | | |
| Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab | TA612 | | |
| Pentosan polysulfate sodium for treating bladder pain syndrome | TA610 | | |
| Ibrutinib with rituximab for treating Waldenstrom's macroglobulinaemia (terminated appraisal) | TA608 | | |
| Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal) | TA609 | | |
| Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease | TA607 | | |
| Lanadelumab for preventing recurrent attacks of hereditary angioedema | TA606 | | |
| Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea | TA605 | | |
| Idelalisib for treating refractory follicular lymphoma | TA604 | | |
| Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal) | TA603 | | |
| Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA602 | | |
| Benralizumab for treating severe eosinophilic asthma | TA565 | | |
| Risankizumab for treating moderate to severe plaque psoriasis | TA596 | | |
| Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal) | TA594 | | |
| Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer | TA595 | | |
| Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis | TA590 | | |
| Letermovir for preventing cytomegalovirus disease after a stem cell transplant | TA591 | | |
| Nusinersen for treating spinal muscular atrophy | TA588 | | |
| Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity | TA589 | | |
| Bisphosphonates for treating osteoporosis | TA464 | | |
| Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality | TA322 | | |
| Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies | TA171 | | |
| Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib | TA586 | | |
| Lenalidomide plus dexamethasone for previously untreated multiple myeloma | TA587 | | |
| Ocrelizumab for treating primary progressive multiple sclerosis | TA585 | | |
| Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes | TA583 | | |
| Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer | TA584 | | |
| Enzalutamide for hormone-relapsed non-metastatic prostate cancer | TA580 | | |
| Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma | TA577 | | |
| Certolizumab pegol for treating moderate to severe plaque psoriasis | TA574 | | |
| Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal) | TA576 | | |
| Tildrakizumab for treating moderate to severe plaque psoriasis | TA575 | | |
| Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes | TA572 | | |
| Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib | TA571 | | |
| Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal) | TA570 | | |
| Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer | TA569 | | |
| Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal) | TA568 | | |
| Cochlear implants for children and adults with severe to profound deafness | TA566 | | |
| Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia | TA561 | | |
| Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma | TA562 | | |
| Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer | TA563 | | |
| Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal) | TA560 | | |
| Regorafenib for previously treated advanced hepatocellular carcinoma | TA555 | | |
| Darvadstrocel for treating complex perianal fistulas in Crohn's disease | TA556 | | |
| Lenvatinib for untreated advanced hepatocellular carcinoma | TA551 | | |
| Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia | TA552 | | |
| Vandetanib for treating medullary thyroid cancer | TA550 | | |
| Decitabine for untreated acute myeloid leukaemia (terminated appraisal) | TA548 | | |
| Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal) | TA549 | | |
| Tofacitinib for moderately to severely active ulcerative colitis | TA547 | | |
| Padeliporfin for untreated localised prostate cancer | TA546 | | |
| Gemtuzumab ozogamicin for untreated acute myeloid leukaemia | TA545 | | |
| Eltrombopag for treating chronic immune thrombocytopenia | TA293 | | |
| Romiplostim for the treatment of chronic immune thrombocytopenia | TA221 | | |
| Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma | TA544 | | |
| Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs | TA543 | | |
| Cabozantinib for untreated advanced renal cell carcinoma | TA542 | | |
| Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia | TA541 | | |
| Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours | TA539 | | |
| Dinutuximab beta for treating neuroblastoma | TA538 | | |
| Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine | TA535 | | |
| Alectinib for untreated ALK-positive advanced non-small-cell lung cancer | TA536 | | |
| Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA537 | | |
| Dupilumab for treating moderate to severe atopic dermatitis | TA534 | | |
| Ocrelizumab for treating relapsing–remitting multiple sclerosis | TA533 | | |
| Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer | TA531 | | |
| Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer | TA529 | | |
| Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy | TA530 | | |
| Beta interferons and glatiramer acetate for treating multiple sclerosis | TA527 | | |
| Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease | TA217 | | |
| Guselkumab for treating moderate to severe plaque psoriasis | TA521 | | |
| Midostaurin for untreated acute myeloid leukaemia | TA523 | | |
| Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma | TA524 | | |
| Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy | TA525 | | |
| Arsenic trioxide for treating acute promyelocytic leukaemia | TA526 | | |
| Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy | TA520 | | |
| Tocilizumab for treating giant cell arteritis | TA518 | | |
| Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen | TA515 | | |
| Cabozantinib for treating medullary thyroid cancer | TA516 | | |
| Brodalumab for treating moderate to severe plaque psoriasis | TA511 | | |
| Tivozanib for treating advanced renal cell carcinoma | TA512 | | |
| Obinutuzumab for untreated advanced follicular lymphoma | TA513 | | |
| Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee | TA508 | | |
| Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer | TA509 | | |
| Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C | TA507 | | |
| Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women | TA160 | | |
| Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women | TA161 | | |
| Pirfenidone for treating idiopathic pulmonary fibrosis | TA504 | | |
| Intrabeam radiotherapy system for adjuvant treatment of early breast cancer | TA501 | | |
| Ibrutinib for treating relapsed or refractory mantle cell lymphoma | TA502 | | |
| Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer | TA503 | | |
| Lenvatinib with everolimus for previously treated advanced renal cell carcinoma | TA498 | | |
| Glecaprevir–pibrentasvir for treating chronic hepatitis C | TA499 | | |
| Ceritinib for untreated ALK-positive non-small-cell lung cancer | TA500 | | |
| Golimumab for treating non-radiographic axial spondyloarthritis | TA497 | | |
| Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer | TA495 | | |
| Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer | TA496 | | |
| Naltrexone–bupropion for managing overweight and obesity | TA494 | | |
| Vismodegib for treating basal cell carcinoma | TA489 | | |
| Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane | TA458 | | |
| Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours | TA488 | | |
| Sarilumab for moderate to severe rheumatoid arthritis | TA485 | | |
| Aflibercept for treating choroidal neovascularisation | TA486 | | |
| Tofacitinib for moderate to severe rheumatoid arthritis | TA480 | | |
| Immunosuppressive therapy for kidney transplant in adults | TA481 | | |
| Immunosuppressive therapy for kidney transplant in children and young people | TA482 | | |
| Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee | TA477 | | |
| Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma | TA478 | | |
| Reslizumab for treating severe eosinophilic asthma | TA479 | | |
| Cetuximab and panitumumab for previously untreated metastatic colorectal cancer | TA439 | | |
| Pembrolizumab for advanced melanoma not previously treated with ipilimumab | TA366 | | |
| Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy | TA428 | | |
| Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab | TA357 | | |
| Sorafenib for treating advanced hepatocellular carcinoma | TA474 | | |
| Dimethyl fumarate for treating moderate to severe plaque psoriasis | TA475 | | |
| Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer | TA476 | | |
| Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck | TA473 | | |
| Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal) | TA468 | | |
| Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal) | TA469 | | |
| Holoclar for treating limbal stem cell deficiency after eye burns | TA467 | | |
| Pemetrexed for the maintenance treatment of non-small-cell lung cancer | TA190 | | |
| Cabozantinib for previously treated advanced renal cell carcinoma | TA463 | | |
| Baricitinib for moderate to severe rheumatoid arthritis | TA466 | | |
| Adalimumab and dexamethasone for treating non-infectious uveitis | TA460 | | |
| Roflumilast for treating chronic obstructive pulmonary disease | TA461 | | |
| Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma | TA462 | | |
| Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people | TA455 | | |
| Ustekinumab for moderately to severely active Crohn's disease after previous treatment | TA456 | | |
| Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal) | TA452 | | |
| Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal) | TA453 | | |
| Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA454 | | |
| Etelcalcetide for treating secondary hyperparathyroidism | TA448 | | |
| Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease | TA449 | | |
| Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia | TA450 | | |
| Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia | TA451 | | |
| Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) | TA444 | | |
| Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA445 | | |
| Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine | TA440 | | |
| Ixekizumab for treating moderate to severe plaque psoriasis | TA442 | | |
| Obeticholic acid for treating primary biliary cholangitis | TA443 | | |
| Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal) | TA438 | | |
| Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal) | TA240 | | |
| Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal) | TA436 | | |
| Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal) | TA437 | | |
| Elotuzumab for previously treated multiple myeloma (terminated appraisal) | TA434 | | |
| Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal) | TA435 | | |
| Ustekinumab for treating active psoriatic arthritis | TA340 | | |
| Ustekinumab for the treatment of adults with moderate to severe psoriasis | TA180 | | |
| Everolimus for advanced renal cell carcinoma after previous treatment | TA432 | | |
| Apremilast for treating active psoriatic arthritis | TA433 | | |
| Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation | TA429 | | |
| Sofosbuvir–velpatasvir for treating chronic hepatitis C | TA430 | | |
| Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib | TA427 | | |
| Everolimus with exemestane for treating advanced breast cancer after endocrine therapy | TA421 | | |
| Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer | TA422 | | |
| Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens | TA423 | | |
| Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer | TA424 | | |
| Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia | TA425 | | |
| Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia | TA426 | | |
| Ticagrelor for preventing atherothrombotic events after myocardial infarction | TA420 | | |
| Dapagliflozin in combination therapy for treating type 2 diabetes | TA288 | | |
| Nivolumab for previously treated advanced renal cell carcinoma | TA417 | | |
| Dapagliflozin in triple therapy for treating type 2 diabetes | TA418 | | |
| Apremilast for treating moderate to severe plaque psoriasis | TA419 | | |
| Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor | TA415 | | |
| Elbasvir–grazoprevir for treating chronic hepatitis C | TA413 | | |
| Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma | TA414 | | |
| Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer | TA411 | | |
| Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases | TA412 | | |
| Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer | TA406 | | |
| Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors | TA407 | | |
| Pegaspargase for treating acute lymphoblastic leukaemia | TA408 | | |
| Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion | TA409 | | |
| Talimogene laherparepvec for treating unresectable metastatic melanoma | TA410 | | |
| Bosutinib for previously treated chronic myeloid leukaemia | TA401 | | |
| Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin | TA402 | | |
| Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer | TA403 | | |
| Degarelix for treating advanced hormone-dependent prostate cancer | TA404 | | |
| Trifluridine–tipiracil for previously treated metastatic colorectal cancer | TA405 | | |
| Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel | TA391 | | |
| Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen | TA259 | | |
| Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts | TA399 | | |
| Nivolumab in combination with ipilimumab for treating advanced melanoma | TA400 | | |
| Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated | TA387 | | |
| Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia | TA393 | | |
| Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia | TA394 | | |
| Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer | TA395 | | |
| Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma | TA396 | | |
| Adalimumab for treating moderate to severe hidradenitis suppurativa | TA392 | | |
| Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes | TA390 | | |
| Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction | TA388 | | |
| Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer | TA389 | | |
| Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis | TA386 | | |
| Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) | TA23 | | |
| Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia | TA385 | | |
| Nivolumab for treating advanced (unresectable or metastatic) melanoma | TA384 | | |
| TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis | TA383 | | |
| Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated | TA377 | | |
| Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy | TA378 | | |
| Nintedanib for treating idiopathic pulmonary fibrosis | TA379 | | |
| Panobinostat for treating multiple myeloma after at least 2 previous treatments | TA380 | | |
| Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal) | TA382 | | |
| Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | | |
| Guidance on the use of imatinib for chronic myeloid leukaemia | TA70 | | |
| Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears | TA369 | | |
| Bortezomib for previously untreated mantle cell lymphoma | TA370 | | |
| Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis | TA373 | | |
| Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy | TA374 | | |
| Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C | TA365 | | |
| Vortioxetine for treating major depressive episodes | TA367 | | |
| Ledipasvir–sofosbuvir for treating chronic hepatitis C | TA363 | | |
| Tolvaptan for treating autosomal dominant polycystic kidney disease | TA358 | | |
| Idelalisib for treating chronic lymphocytic leukaemia | TA359 | | |
| Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal) | TA362 | | |
| Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy | TA352 | | |
| Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal) | TA353 | | |
| Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism | TA354 | | |
| Naloxegol for treating opioid‑induced constipation | TA345 | | |
| Aflibercept for treating diabetic macular oedema | TA346 | | |
| Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer | TA347 | | |
| Everolimus for preventing organ rejection in liver transplantation | TA348 | | |
| Secukinumab for treating moderate to severe plaque psoriasis | TA350 | | |
| Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal) | TA351 | | |
| Omalizumab for previously treated chronic spontaneous urticaria | TA339 | | |
| Vedolizumab for treating moderately to severely active ulcerative colitis | TA342 | | |
| Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism | TA341 | | |
| Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia | TA343 | | |
| Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome | TA335 | | |
| Empagliflozin in combination therapy for treating type 2 diabetes | TA336 | | |
| Rifaximin for preventing episodes of overt hepatic encephalopathy | TA337 | | |
| Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy | TA329 | | |
| Sofosbuvir for treating chronic hepatitis C | TA330 | | |
| Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment | TA333 | | |
| Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) | TA334 | | |
| Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma | TA269 | | |
| Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism | TA327 | | |
| Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy | TA323 | | |
| Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block | TA324 | | |
| Nalmefene for reducing alcohol consumption in people with alcohol dependence | TA325 | | |
| Imatinib for the adjuvant treatment of gastrointestinal stromal tumours | TA326 | | |
| Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome and/or atrioventricular block | TA88 | | |
| Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma | TA321 | | |
| Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis | TA320 | | |
| Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen | TA316 | | |
| Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes | TA317 | | |
| Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma | TA319 | | |
| Canagliflozin in combination therapy for treating type 2 diabetes | TA315 | | |
| Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure | TA314 | | |
| Teriflunomide for treating relapsing–remitting multiple sclerosis | TA303 | | |
| Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer | TA310 | | |
| Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation | TA311 | | |
| Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis | TA308 | | |
| Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy | TA307 | | |
| Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip | TA304 | | |
| Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion | TA305 | | |
| Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma | TA306 | | |
| Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people | TA300 | | |
| Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal) | TA302 | | |
| Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C | TA106 | | |
| Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C | TA75 | | |
| Pazopanib for the first-line treatment of advanced renal cell carcinoma | TA215 | | |
| Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder | TA292 | | |
| Aflibercept solution for injection for treating wet age‑related macular degeneration | TA294 | | |
| Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism | TA287 | | |
| Mirabegron for treating symptoms of overactive bladder | TA290 | | |
| Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer | TA284 | | |
| Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer | TA285 | | |
| Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal) | TA286 | | |
| Omalizumab for treating severe persistent allergic asthma | TA278 | | |
| Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures | TA279 | | |
| Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis | TA276 | | |
| Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal) | TA277 | | |
| Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract | TA272 | | |
| Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal) | TA273 | | |
| Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma | TA268 | | |
| Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal) | TA270 | | |
| Dronedarone for the treatment of non-permanent atrial fibrillation | TA197 | | |
| Mannitol dry powder for inhalation for treating cystic fibrosis | TA266 | | |
| Ivabradine for treating chronic heart failure | TA267 | | |
| Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours | TA265 | | |
| Alteplase for treating acute ischaemic stroke | TA264 | | |
| Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer | TA263 | | |
| Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism | TA261 | | |
| Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 | TA257 | | |
| Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer | TA258 | | |
| Botulinum toxin type A for the prevention of headaches in adults with chronic migraine | TA260 | | |
| Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis | TA254 | | |
| Pharmalgen for the treatment of bee and wasp venom allergy | TA246 | | |
| Tocilizumab for the treatment of rheumatoid arthritis | TA247 | | |
| Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy | TA242 | | |
| Rituximab for the first-line treatment of stage III-IV follicular lymphoma | TA243 | | |
| Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults | TA245 | | |
| Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer | TA118 | | |
| Tocilizumab for the treatment of systemic juvenile idiopathic arthritis | TA238 | | |
| Fulvestrant for the treatment of locally advanced or metastatic breast cancer | TA239 | | |
| Mifamurtide for the treatment of osteosarcoma | TA235 | | |
| Ticagrelor for the treatment of acute coronary syndromes | TA236 | | |
| Bortezomib and thalidomide for the first‑line treatment of multiple myeloma | TA228 | | |
| Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion | TA229 | | |
| Agomelatine for the treatment of major depressive episodes (terminated appraisal) | TA231 | | |
| Myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction | TA73 | | |
| Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer | TA227 | | |
| Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs | TA225 | | |
| Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma | TA226 | | |
| Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease | TA223 | | |
| Golimumab for the treatment of psoriatic arthritis | TA220 | | |
| Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia | TA218 | | |
| Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer | TA214 | | |
| Bendamustine for the first-line treatment of chronic lymphocytic leukaemia | TA216 | | |
| Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years | TA213 | | |
| Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events | TA210 | | |
| Prucalopride for the treatment of chronic constipation in women | TA211 | | |
| Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer | TA212 | | |
| Trastuzumab for the treatment of HER2-positive metastatic gastric cancer | TA208 | | |
| Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours | TA209 | | |
| Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours | TA86 | | |
| Denosumab for the prevention of osteoporotic fractures in postmenopausal women | TA204 | | |
| Bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab (terminated appraisal) | TA206 | | |
| Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal) | TA207 | | |
| Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C | TA200 | | |
| Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor | TA195 | | |
| Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis | TA199 | | |
| Capecitabine for the treatment of advanced gastric cancer | TA191 | | |
| Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer | TA192 | | |
| Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia | TA193 | | |
| Human growth hormone (somatropin) for the treatment of growth failure in children | TA188 | | |
| Infliximab and adalimumab for the treatment of Crohn's disease | TA187 | | |
| Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes | TA47 | | |
| Topotecan for the treatment of relapsed small-cell lung cancer | TA184 | | |
| Topotecan for the treatment of recurrent and stage IVB cervical cancer | TA183 | | |
| Guidance on the use of electroconvulsive therapy | TA59 | | |
| Sunitinib for the treatment of gastrointestinal stromal tumours | TA179 | | |
| Pemetrexed for the first-line treatment of non-small-cell lung cancer | TA181 | | |
| Alitretinoin for the treatment of severe chronic hand eczema | TA177 | | |
| Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma | TA178 | | |
| Tenofovir disoproxil for the treatment of chronic hepatitis B | TA173 | | |
| Rituximab for the first-line treatment of chronic lymphocytic leukaemia | TA174 | | |
| Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults | TA170 | | |
| Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma | TA169 | | |
| Amantadine, oseltamivir and zanamivir for the treatment of influenza | TA168 | | |
| Machine perfusion systems and cold static storage of kidneys from deceased donors | TA165 | | |
| Infliximab for acute exacerbations of ulcerative colitis | TA163 | | |
| Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin | TA159 | | |
| Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults | TA157 | | |
| Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza | TA158 | | |
| Routine antenatal anti-D prophylaxis for women who are rhesus D negative | TA156 | | |
| Entecavir for the treatment of chronic hepatitis B | TA153 | | |
| Telbivudine for the treatment of chronic hepatitis B | TA154 | | |
| Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus | TA151 | | |
| Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal) | TA148 | | |
| Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal) | TA149 | | |
| Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck | TA145 | | |
| Adalimumab for the treatment of adults with psoriasis | TA146 | | |
| Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over | TA138 | | |
| Structural neuroimaging in first-episode psychosis | TA136 | | |
| Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma | TA137 | | |
| Infliximab for the treatment of adults with psoriasis | TA134 | | |
| Pemetrexed for the treatment of malignant pleural mesothelioma | TA135 | | |
| Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years | TA131 | | |
| Bortezomib monotherapy for relapsed multiple myeloma | TA129 | | |
| Stapled haemorrhoidopexy for the treatment of haemorrhoids | TA128 | | |
| Pemetrexed for the treatment of non-small-cell lung cancer | TA124 | | |
| Varenicline for smoking cessation | TA123 | | |
| Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma | TA121 | | |
| Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia | TA119 | | |
| Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy | TA117 | | |
| Methadone and buprenorphine for the management of opioid dependence | TA114 | | |
| Naltrexone for the management of opioid dependence | TA115 | | |
| Gemcitabine for the treatment of metastatic breast cancer | TA116 | | |
| Laparoscopic surgery for colorectal cancer | TA105 | | |
| Etanercept and efalizumab for the treatment of adults with psoriasis | TA103 | | |
| Docetaxel for the treatment of hormone-refractory metastatic prostate cancer | TA101 | | |
| Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer | TA100 | | |
| Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B | TA96 | | |
| HealOzone for the treatment of tooth decay (occlusal pit and fissure caries and root caries) | TA92 | | |
| Guidance on the use of paclitaxel in the treatment of ovarian cancer | TA55 | | |
| Laparoscopic surgery for inguinal hernia repair | TA83 | | |
| Tacrolimus and pimecrolimus for atopic eczema | TA82 | | |
| Frequency of application of topical corticosteroids for atopic eczema | TA81 | | |
| Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia | TA77 | | |
| Fluid-filled thermal balloon and microwave endometrial ablation techniques for heavy menstrual bleeding | TA78 | | |
| Pre-hospital initiation of fluid replacement therapy in trauma | TA74 | | |
| Guidance on the use of liquid-based cytology for cervical screening | TA69 | | |
| Human growth hormone (somatropin) in adults with growth hormone deficiency | TA64 | | |
| Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer | TA61 | | |
| Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction | TA52 | | |
| Guidance on the use of ultrasound locating devices for placing central venous catheters | TA49 | | |
| Inhaler devices for routine treatment of chronic asthma in older children (aged 5 to 15 years) | TA38 | | |
| Guidance on the use of trastuzumab for the treatment of advanced breast cancer | TA34 | | |
| Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia | TA29 | | |
| Guidance on the use of riluzole (Rilutek) for the treatment of motor neurone disease | TA20 | | |
| Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma | TA10 | | |
| Guidance on the extraction of wisdom teeth | TA1 | | |